98%
921
2 minutes
20
Background And Aims: Collusion, the practice of concealing a diagnosis or prognosis from a close relative to prevent emotional distress, is a complex issue in cancer care. This study aimed to estimate the prevalence of collusion among cancer patients and identify the associated factors, including educational status, time since diagnosis, and prognosis.
Methods: This 6-month cross-sectional study recruited 121 consenting cancer patients (aged >18 years) via convenient sampling at a tertiary care center in South India. Patients with psychiatric conditions or communication difficulties were excluded. The data were collected through qualitative interviews using a modified collusion questionnaire.
Results: The overall prevalence of collusion was 26.4%. Significant associations were found with educational status (P = 0.024), with collusion being highest among those with primary education (40.7%) and lowest in postgraduates (12.2%). Collusion was also significantly associated with time since diagnosis (P < 0.001), being 88.9% within 1 month and decreasing to 54.2% by 6 months. Caregivers frequently colluded (P < 0.001) even when the disease was considered partly curable. Among the collusion positive cases, 96.9% of the caregivers were unwilling to discuss the diagnosis and 87.5% unwilling to inform patients about the disease's course or outcome.
Conclusion: Collusion is prevalent in cancer patients, particularly among those with lower education levels and in the early postdiagnosis period. Caregivers often withhold comprehensive information, highlighting a need for improved communication strategies in oncology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/aam.aam_215_25 | DOI Listing |
Nutr Clin Pract
September 2025
Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.
View Article and Find Full Text PDFBMC Cancer
September 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.
View Article and Find Full Text PDFBreast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.